Zevor-cel (CT053)3
Zevor-cel (CT053)
Zevor-cel (CT053)
Conventional
Zevorcabtagene autoleucel (Zevor-cel, R&D code: CT053) is a fully human, autologous BCMA CAR T-cell product for the treatment of R/R MM. Zevorcabtagene autoleucel was approved by the NMPA on February 23, 2024, for the treatment of adult patients with relapsed or refractory multiple myeloma who have previously progressed after at least 3 lines of therapy (at least one proteasome inhibitor and immunomodulator).
Investigator-Initiated Trial
?
Phase I/II Clinical Trial (LUMMICAR STUDY 1)
? Phase 1b/2 Clinical Trial (LUMMICAR STUDY 2)
RMAT designation, FDA
for relapsed and/or refractory multiple myeloma (R/R MM)
Orphan Drug designation, FDA
for multiple myeloma (MM)
Conventional
Satri-cel (CT041)
Satri-cel (CT041)
Satri-cel (CT041)
Conventional
Satricabtagene autoleucel (Satri-cel, R&D code: CT041) is an autologous humanized Claudin18.2 CAR T-cell therapy product. It was approved by the NMPA in June 2026, for the treatment of patients with Claudin18.2-positive, HER2-negative advanced gastric/ gastroesophageal junction adenocarcinoma (G/GEJA) who have failed at least two prior lines of therapy.
Investigator-initiated trials for solid tumors
?
Phase Ib clinical trial for advanced G/GEJA and PC and a confirmatory Phase II clinical trial for advanced G/GEJA
?
Phase Ib clinical trial for PC adjuvant therapy
?
Investigator-initiated trial?for G/GEJA?adjuvant therapy
?
Investigator-initiated trial for G/GEJA first-line sequential therapy
RMAT designation, FDA
for advanced gastric /gastroesophageal junction adenocarcinoma (G/GEJA) with Claudin18.2-positive tumor
Orphan Drug designation, FDA
for gastric /gastroesophageal junction cancer(G/GEJA)
Orphan Medicinal Product designation, EMA
for?gastric cancer
PRIME designation, EMA
for?patients with advanced gastric cancer who have failed at least 2 prior lines of systemic therapy
Breakthrough Therapy designation, NMPA
for advanced gastric/gastroesophageal junction cancer (G/GEJC) in patients who have failed at least two prior lines of therapy.
Conventional
CT0596
CT0596
CT0596
THANK-u Plus?
CT0596 is an allogeneic BCMA-targeted CAR-T therapy developed using CARsgen’s proprietary THANK-u Plus? platform.?CT0596 demonstrated preliminary favorable tolerability and encouraging efficacy signals and CAR-T expansion across all predefined dose levels.
Investigator-initiated trial for R/R MM and PCL?(Shanghai Changzheng Hospital)
?
Investigator-initiated trial for R/R MM and PCL?(The First Affiliated Hospital of Soochow University)
?
Investigator-initiated trial for PCL (Institute of Hematology & Blood Diseases Hospital)
THANK-u Plus?
THANK-uCAR?
THANK-uCAR?
THANK-uCAR?
THANK-uCAR?
In vivo CAR-T
R/R MM: relapsed/refractory multiple myeloma; G/GEJA: gastric /gastroesophageal junction adenocarcinoma;? GC: gastric cancer;? PC: pancreatic cancer;? PCL: plasma cell leukemia; AML: acute myeloid leukemia; HCC: hepatocellular carcinoma
1 All product candidates are self-developed with global rights
2 Phase II trials of some indications are pivotal studies
3 Core Product. Commercial rights in Chinese mainland have been granted to Huadong Medicine (SZ: 000963).